These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 27198052

  • 21. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Aw A, Brown JR.
    Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase.
    Davids MS, Brown JR.
    Future Oncol; 2014 May; 10(6):957-67. PubMed ID: 24941982
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Zou YX, Zhu HY, Li XT, Xia Y, Miao KR, Zhao SS, Wu YJ, Wang L, Xu W, Li JY.
    Hematol Oncol; 2019 Oct; 37(4):392-400. PubMed ID: 31420873
    [Abstract] [Full Text] [Related]

  • 32. PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.
    Jones D, Woyach JA, Zhao W, Caruthers S, Tu H, Coleman J, Byrd JC, Johnson AJ, Lozanski G.
    Leukemia; 2017 Jul; 31(7):1645-1647. PubMed ID: 28366935
    [No Abstract] [Full Text] [Related]

  • 33. A new era of treatment for chronic lymphocytic leukaemia?
    Brown JR.
    Lancet Oncol; 2014 Jan; 15(1):3-5. PubMed ID: 24332240
    [No Abstract] [Full Text] [Related]

  • 34. Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.
    Gayko U, Fung M, Clow F, Sun S, Faust E, Price S, James D, Doyle M, Bari S, Zhuang SH.
    Ann N Y Acad Sci; 2015 Nov; 1358():82-94. PubMed ID: 26348626
    [Abstract] [Full Text] [Related]

  • 35. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.
    Wang Y, Zhang LL, Champlin RE, Wang ML.
    Clin Pharmacol Ther; 2015 May; 97(5):455-68. PubMed ID: 25669675
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.
    Gozzetti A, Candi V, Brambilla CZ, Papini G, Fabbri A, Bocchia M.
    Anticancer Agents Med Chem; 2017 May; 17(8):1040-1045. PubMed ID: 27697038
    [Abstract] [Full Text] [Related]

  • 38. The promising impact of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the management of lymphoid malignancies.
    Bhatt V, Alejandro L, Michael A, Ganetsky A.
    Pharmacotherapy; 2014 Mar; 34(3):303-14. PubMed ID: 24338680
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas.
    Alinari L, Quinion C, Blum KA.
    Clin Pharmacol Ther; 2015 May; 97(5):469-77. PubMed ID: 25670208
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.